Delayed onset CMV disease in solid organ transplant recipients

Transplant Immunology

Volumn 21, Issue 1, 2009, Pages 1-9

  Husain, Shahid ^a   Pietrangeli, Carolynn E ^b   Zeevi, Adriana ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CTI Clinical Trial and Consulting Services   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Late CMV; Solid organ transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CYTOMEGALOVIRUS VACCINE; GANCICLOVIR; IMMUNOGLOBULIN; VALGANCICLOVIR;

CANCER RISK; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; GRAFT FAILURE; HUMAN; IMMUNOLOGICAL MONITORING; INFECTION PREVENTION; INFECTION RISK; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VACCINATION; VIRUS REPLICATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INCIDENCE; ORGAN TRANSPLANTATION; RISK FACTORS; TRANSPLANTATION; VIRUS ACTIVATION;

EID: 64449085766     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.12.004     Document Type: Review

References (112)

1. Naraqi S. Cytomegalovirus. In: Belshe E. (Ed). Textbook of human virology. 2nd ed. (1991), Mosby-Year Book Inc, St Louis 889-924
2. Rowshani A.T., Bemelman F.J., van Leeuwen E.M., van Lier R.A., and ten Berge I.J. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79 4 (2005 Feb 27) 381-386
3. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 24 (1998 Jun 11) 1741-1751
4. Fishman J.A., Emery V., Freeman R., Pascual M., Rostaing L., Schlitt H.J., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21 2 (2007 Mar-Apr) 149-158
5. Rubin R.H. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr Opin Infect Dis 20 4 (2007 Aug) 399-407
6. Rubin R.H. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. Jama 261 24 (1989 Jun 23-30) 3607-3609
7. Nordoy I., Muller F., Nordal K.P., Rollag H., Lien E., Aukrust P., et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 181 1 (2000 Jan) 51-57
8. Kas-Deelen A.M., de Maar E.F., Harmsen M.C., Driessen C., van Son W.J., and The T.H. Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection. J Infect Dis 181 2 (2000 Feb) 721-724
9. Grefte A., van der Giessen M., van Son W., and The T.H. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 167 2 (1993 Feb) 270-277
10. Emery V. Facing the facts: the indirect effects of cytomegalovirus. Transplantation 84 6 Suppl (2007 September 27) S7-S10
11. Humar A., Gillingham K.J., Payne W.D., Dunn D.L., Sutherland D.E., and Matas A.J. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 68 12 (1999 Dec 27) 1879-1883
12. Cainelli F., and Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship?. Lancet Infect Dis 2 9 (2002 Sep) 539-549
13. Potena L., and Valantine H.A. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 20 4 (2007 Aug) 425-431
14. Hartmann A., Sagedal S., and Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 82 2 Suppl (2006 Jul 27) S15-S17
15. Duncan S.R., Paradis I.L., Yousem S.A., Similo S.L., Grgurich W.F., Williams P.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 146 6 (1992 Dec) 1419-1425
16. Schnitzler M.A., Lowell J.A., Hardinger K.L., Boxerman S.B., Bailey T.C., and Brennan D.C. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant 3 4 (2003 Apr) 445-451
17. Cytomegalovirus. Am J Transplant 4 Suppl 10 (2004 Nov) 51-58
18. Sia I.G., and Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 13 1 (2000 Jan) 83-121 table of contents
19. Speich R., and van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis 33 Suppl 1 (2001 Jul 1) S58-S65
20. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 8 (2002 Apr 15) 1094-1097
21. Preiksaitis J.K., Brennan D.C., Fishman J., and Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5 2 (2005 Feb) 218-227
22. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes. 2004 Dec;11(3):77-86.
23. Paya C., and Razonable R.R. Cytomegaloviris infection after solid organ transplantation. In: Bowden R.A., Ljungman P., and Paya C. (Eds). Transplant infections. 2nd ed (2003), Lippincott Williams and Wilkens, Philadelphia 298-325
24. Rubin R.H., Kemmerly S.A., Conti D., Doran M., Murray B.M., Neylan J.F., et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2 3 (2000 Sep) 112-117
25. Dauber J.H., Paradis I.L., and Dummer J.S. Infectious complications in pulmonary allograft recipients. Clin Chest Med 11 2 (1990 Jun) 291-308
26. Duncan A.J., Dummer J.S., Paradis I.L., Dauber J.H., Yousem S.A., Zenati M.A., et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 5 Pt 1 (1991 Sep-Oct;10) 638-644 discussion 45-6
27. Luckraz H., Sharples L., McNeil K., Wreghitt T., and Wallwork J. Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant 22 3 (2003 Mar) 287-291
28. Husain S., and Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 17 4 (2002 Dec) 310-314
29. Sharples L.D., Tamm M., McNeil K., Higenbottam T.W., Stewart S., and Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation-early risk factors. Transplantation 61 4 (1996 Feb 27) 560-566
30. Gane E., Saliba F., Valdecasas G.J., O'Grady J., Pescovitz M.D., Lyman S., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350 9093 (1997 Dec 13) 1729-1733
31. Sagedal S., Nordal K.P., Hartmann A., Degre M., Holter E., Foss A., et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 70 8 (2000 Oct 27) 1166-1174
32. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., and Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185 1 (2002 Jan 1) 20-27
33. Slifkin M., Tempesti P., Poutsiaka D.D., and Snydman D.R. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 33 7 (2001 Oct 1) E62-68
34. Singh N., Zeevi A., Gayowski T., and Marino I.R. Late onset cytomegalovirus disease in liver transplant recipients: de novo reactivation in recurrent hepatitis C virus hepatitis. Transpl Int 11 4 (1998) 308-311
35. Boeckh M., and Riddell S.R. Immunologic predictors of late cytomegalovirus disease after solid organ transplantation-an elusive goal?. J Infect Dis 195 5 (2007 Mar 1) 615-617
36. Potena L., Holweg C.T., Vana M.L., Bashyam L., Rajamani J., McCormick A.L., et al. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol 45 6 (2007 Jun) 1804-1810
37. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health-Syst Pharm 62 8 Suppl 1 (2005 Apr 15) S7-13
38. Limaye A.P., Bakthavatsalam R., Kim H.W., Kuhr C.S., Halldorson J.B., Healey P.J., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78 9 (2004 Nov 15) 1390-1396
39. Shibolet O., Ilan Y., Kalish Y., Safadi R., Ashur Y., Eid A., et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 16 12 (2003 Dec) 861-865
40. Gamadia L.E., Remmerswaal E.B., Weel J.F., Bemelman F., van Lier R.A., and Ten Berge I.J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101 7 (2003 Apr 1) 2686-2692
41. Shlobin O.A., West E.E., Lechtzin N., Miller S.M., Borja M., Orens J.B., et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 176 4 (2006 Feb 15) 2625-2634
42. Westall G., Kotsimbos T., and Brooks A. CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation. Am J Transplant 6 3 (2006 Mar) 577-584
43. Tu W., Potena L., Stepick-Biek P., Liu L., Dionis K.Y., Luikart H., et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 114 15 (2006 Oct 10) 1608-1615
44. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., and Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 7 (1994 Apr 1) 1971-1979
45. Jochimsen F., Westhoff T., Engelmann E., Schafer J.H., Offermann G., and Zidek W. Late-onset cytomegalovirus reactivation in critically ill renal transplant patients. Transplantation 76 2 (2003 Jul 27) 430-432
46. Prosch S., Staak K., Stein J., Liebenthal C., Stamminger T., Volk H.D., et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. Virology 208 1 (1995 Apr 1) 197-206
47. Zeevi A., Morel P., Spichty K., Dauber J., Yousem S., Williams P., et al. Clinical significance of CMV-specific T helper responses in lung transplant recipients. Hum Immunol 59 12 (1998 Dec) 768-775
48. La Rosa C., Limaye A.P., Krishnan A., Longmate J., and Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195 5 (2007 March) 633-644
49. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201 7 (2005 Apr 4) 1031-1036
50. Corales R., Chua J., Mawhorter S., Young J.B., Starling R., Tomford J.W., et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?. Transpl Infect Dis 2 3 (2000 Sep) 133-139
51. Goldfarb N.S., Avery R.K., Goormastic M., Mehta A.C., Schilz R., Smedira N., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 71 2 (2001 Jan 27) 242-246
52. Yamani M.H., Avery R.K., Mawhorter S.D., Young J.B., Ratliff N.B., Hobbs R.E., et al. Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J Heart Lung Transplant 20 4 (2001 Apr) 425-430
53. Braun W.E., Avery R., Gifford Jr. R.W., and Straffon R.A. Life after 20 years with a kidney transplant: redefined disease profiles and an emerging nondiabetic vasculopathy. Transplant Proc 29 1-2 (1997 Feb-Mar) 247-249
54. Avery R. Management of late, recurrent, and resistant cytomegalovirus in transplant patients. Transplant Rev 21 2 (2007 April) 65-76
55. Arthurs S.K., Eid A.J., Pedersen R.A., Kremers W.K., Cosio F.G., Patel R., et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46 6 (2008 Mar 15) 840-846
56. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 9230 (2000 Aug 19) 645-649
57. Limaye A.P. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 35 7 (2002 Oct 1) 866-872
58. Aitken C., Barrett-Muir W., Raftery M., and Breuer J. The clinical significance of ganciclovir resistance in a renal transplant patient. Nephrol Dial Transplant 14 4 (1999 Apr) 1050-1051
59. Isada C.M., Yen-Lieberman B., Lurain N.S., Schilz R., Kohn D., Longworth D.L., et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 4 4 (2002 Dec) 189-194
60. Radha R., Jordan S., Puliyanda D., Bunnapradist S., Petrosyan A., Amet N., et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 5 1 (2005 Jan) 110-117
61. Razonable R.R., Rivero A., Rodriguez A., Wilson J., Daniels J., Jenkins G., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184 11 (2001 Dec 1) 1461-1464
62. Kanj S.S., Sharara A.I., Clavien P.A., and Hamilton J.D. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 22 3 (1996 Mar) 537-549
63. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 4 (2004 Apr) 611-620
64. Levitsky J., Freifeld G., Bargenquast K., Stevens R.B., and Kalil A.C. The clincial value of quantatative polymerase chain reaction on cytomegalovirus infection after solid organ transplantation. Am J Transplant 4 8 (2004 March) 339
65. Murray B.M., and Subramaniam S. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transpl Infect Dis 6 1 (2004 Mar) 3-9
66. Li F., Kenyon K.W., Kirby K.A., Fishbein D.P., Boeckh M., and Limaye A.P. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 45 4 (2007 Aug 15) 439-447
67. Schleiss M. Progress in cytomegalovirus vaccine development. Herpes 12 3 (2005 Dec) 66-75
68. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195 6 (2007 Mar 15) 789-798
69. Doyle A.M., Warburton K.M., Goral S., Blumberg E., Grossman R.A., and Bloom R.D. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 81 8 (2006 Apr 27) 1106-1111
70. IMPACT Clinical Trial. [cited; Available from: http://clinicaltrials.gov/ct2/show/NCT00294515?term=IMPACT+valcyte&r ank=1
71. Small L.N., Lau J., and Snydman D.R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 43 7 (2006 Oct 1) 869-880
72. Kalil A.C., Levitsky J., Lyden E., Stoner J., and Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143 12 (2005 Dec 20) 870-880
73. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11 2 (2001 Mar-Apr) 83-86
74. Razonable R.R., van Cruijsen H., Brown R.A., Wilson J.A., Harmsen W.S., Wiesner R.H., et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 187 11 (2003 Jun 1) 1801-1808
75. Snydman D.R. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 12 Suppl 7 (1990 Sep-Oct) S839-S848
76. Cytogam® Prescribing Information. King of Prussia, PA: CSL Behring, LLV; 2007.
77. Snydman D.R., Werner B.G., Dougherty N.N., Griffith J., Rubin R.H., Dienstag J.L., et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 119 10 (1993 Nov 15) 984-991
78. Falagas M.E., Snydman D.R., Ruthazer R., Griffith J., Werner B.G., Freeman R., et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 5 Pt 1 (1997 Oct;11) 432-437
79. Falagas M.E., Paya C., Ruthazer R., Badley A., Patel R., Wiesner R., et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 66 8 (1998 Oct 27) 1020-1028
80. Weill D., Lock B.J., Wewers D.L., Young K.R., Zorn G.L., Early L., et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 3 4 (2003 Apr) 492-496
81. Valantine H.A., Luikart H., Doyle R., Theodore J., Hunt S., Oyer P., et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 72 10 (2001 Nov 27) 1647-1652
82. Potena L., Holweg C.T., Chin C., Luikart H., Weisshaar D., Narasimhan B., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82 3 (2006 Aug 15) 398-405
83. Yamani M.H., Avery R., Mawhorter S.D., McNeill A., Cook D., Ratliff N.B., et al. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant 24 11 (2005 Nov) 1766-1769
84. George M.J., Snydman D.R., Werner B.G., Dougherty N.N., Griffith J., Rohrer R.H., et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 5 Suppl 4 (1993 Oct;25) 22-24
85. Sarmiento E., Fernandez-Yanez J., Munoz P., Palomo J., Rodriguez-Molina J.J., Bermejo J., et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol 5 1 (2005 Jan) 97-101
86. Hodson E.M., Jones C.A., Strippoli G.F., Webster A.C., and Craig J.C. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2 (2007) CD005129
87. Bonaros N., Mayer B., Schachner T., Laufer G., and Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 22 1 (2008 Jan-Feb) 89-97
88. Zeevi A., Husain S., Spichty K.J., Raza K., Woodcock J.B., Zaldonis D., et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 7 2 (2007 Feb) 471-475
89. Westall G.P., Mifsud N.A., and Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 8 8 (2008 Aug) 1749-1754
90. Kumar D., Chernenko S., Moussa G., Preiksaitis J., Doucette K., Manuel O., et al. A prospective study of CD8+ T-cell mediated immunity to Cytomegalovirus (CMV) as a predictor of CMV disease. Am J Transplant 8 Suppl 2 (2008) 266 Abstract 331
91. Asberg A., Humar A., Rollag H., Jardine A.G., Mouas H., Pescovitz M.D., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7 9 (2007 Sep) 2106-2113
92. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 185 2 (2002 Jan 15) 162-169
93. Lurain N.S., Bhorade S.M., Pursell K.J., Avery R.K., Yeldandi V.V., Isada C.M., et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 186 6 (2002 Sep 15) 760-768
94. Drew W.L., Paya C.V., and Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 1 4 (2001 Nov) 307-312
95. Erice A., Gil-Roda C., Perez J.L., Balfour Jr. H.H., Sannerud K.J., Hanson M.N., et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 175 5 (1997 May) 1087-1092
96. Mylonakis E., Kallas W.M., and Fishman J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 34 10 (2002 May 15) 1337-1341
97. Avery R.K., Bolwell B.J., Yen-Lieberman B., Lurain N., Waldman W.J., Longworth D.L., et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 34 12 (2004 Dec) 1071-1075
98. Chou S., and Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 50 10 (2006 Oct) 3470-3472
99. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 78 13 (2004 Jul) 7124-7130
100. Pescovitz M.D. Antiviral therapies for cytomegalovirus in solid-organ transplantation. Transplantation 84 6 Suppl (2007 September 27) S2-S6
101. Jacobson M.A., Sinclair E., Bredt B., Agrillo L., Black D., Epling C.L., et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 24 25 (2006 Jun 19) 5311-5319
102. Gonczol E., and Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 1 3 (2001 May) 401-412
103. John G.T., Manivannan J., Chandy S., Peter S., and Jacob C.K. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 77 9 (2004 May 15) 1460-1461
104. John G.T., Manivannan J., Chandy S., Peter S., Fleming D.H., Chandy S.J., et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 37 10 (2005 Dec) 4303-4305
105. Legendre C., and Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 46 5 (2008 Mar 1) 732-740
106. Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. Clin Infect Dis 47 2 (2008 Jul 15) 296-297 author reply 7
107. Becker B.N., Becker Y.T., Leverson G.E., Simmons W.D., Sollinger H.W., and Pirsch J.D. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 39 5 (2002 May) 1088-1095
108. Axelrod D., Leventhal J.R., Gallon L.G., Parker M.A., and Kaufman D.B. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. Am J Transplant 5 6 (2005 Jun) 1423-1429
109. Akalin E., Sehgal V., Ames S., Hossain S., Daly L., Barbara M., et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3 6 (2003 Jun) 731-735
110. Arthurs S.K., Eid A.J., Pedersen R.A., Dierkhising R.A., Kremers W.K., Patel R., et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transplant 13 12 (2007 Dec) 1703-1709
111. Humar A., Kumar D., Preiksaitis J., Boivin G., Siegal D., Fenton J., et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 5 6 (2005 Jun) 1462-1468
112. Zamora M.R., Nicolls M.R., Hodges T.N., Marquesen J., Astor T., Grazia T., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 4 10 (2004 Oct) 1635-1642